What's in Dr.med. Sabine Schoenfeld's pipeline?

Dr.med. Sabine Schoenfeld has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Dr.med. Sabine Schoenfeld's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/dr-med-sabine-schoenfeld.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Dr.med. Sabine Schoenfeld — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dr.med. Sabine Schoenfeld pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
morphine and droperidol	morphine and droperidol	marketed	Opioid analgesic with antipsychotic/antiemetic	Mu opioid receptor (morphine); dopamine D2 receptor (droperidol)	Pain Management, Anesthesia

Therapeutic area mix

Pain Management, Anesthesia · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Dr.med. Sabine Schoenfeld:

Cite this brief

Drug Landscape (2026). Dr.med. Sabine Schoenfeld — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/dr-med-sabine-schoenfeld. Accessed 2026-05-17.